Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and early anti-tumor effects of new drugs or drug combinations given around the time of surgery. This study focuses on adults with locally advanced but operable gastric, gastroesophageal junction, or esophageal adenocarcinoma who have not yet received treatment for their cancer. It is a Phase II, open-label study conducted at multiple centers, consisting of various sub-studies to test different treatment options. Participants will be assigned to specific sub-studies where they receive different combinations of investigational drugs such as Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan T-DXd, and chemotherapy agents like 5-Fluorouracil, Capecitabine, and FLOT chemotherapy. Treatments include neoadjuvant therapy before surgery followed by adjuvant therapy after surgery, with dosing schedules defined per sub-study. Some drugs are given as intravenous infusions, while others like Capecitabine are taken orally. During the study, participants will have regular assessments including monitoring for adverse events and serious adverse events, evaluation of tumor response such as pathological complete response and tumor downstaging, and surgery completion rates. Researchers will also measure survival outcomes and drug levels in the blood. The study lasts up to 38 months per sub-study, including treatment and follow-up, to fully assess safety and preliminary effectiveness.